Printer Friendly
The Free Library
14,634,628 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Stratagene Announces New National Market Listing.


Business Editors/Health/Medical Writers

LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BUSINESS WIRE)--June 3, 2004

Stratagene Corp. (Nasdaq:STGN), a leader in the development of clinical diagnostic instrument systems and reagents, and innovative technologies that enhance gene discovery and biomedical bi·o·med·i·cal
adj.
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
 target identification, today announced that following the successful completion of the merger of Hycor Biomedical and Stratagene, which closed on June 2, 2004, the company has satisfied the NASDAQ National Market's initial listing requirements Listing requirements

Requirements, including minimum shares outstanding, market value, and income, that are laid down by an exchange for any stock to be listed for trading.
 and the company's common stock will begin trading on the NASDAQ National Market under the ticker symbol Ticker Symbol

An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors
 "STGN." Trading will begin at market open, June 3, 2004.

In addition, Stratagene will release financial results for Stratagene's operations after market close on June 10, 2004 and will conduct a conference call the morning of June 11, 2004. Specific details on the conference call will be announced next week. Hycor Biomedical separately released its financial results on April 27, 2004.

About Stratagene Corp.

Stratagene is a leader in developing, marketing and manufacturing innovative life science consumables, instrumentation, and diagnostic products for a variety of human medical conditions. The company's life science research operations support advances in science by inventing, manufacturing and distributing products that simplify, accelerate and improve research. These products are used throughout the academic, industrial, and government research sectors in fields spanning molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller , genomics, proteomics, drug discovery and toxicology. The company's diagnostic operations develop and manufacture products including high-quality automated instrument and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders Autoimmune Disorders Definition

Autoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction.
 and urinalysis controls. More information is available at http://www.stratagene.com.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 3, 2004
Words:265
Previous Article:Docucorp to Participate in Retail Solutions 2004.
Next Article:Monster Employment Index Shows Rise in Online Job Demand In May.



Related Articles
Hycor and Stratagene Announce Definitive Merger Agreement.
Dealmaking. (Wall Street West).(Brief Article)
Hycor and Stratagene File Registration Statement on Form S-4.
Hycor Biomedical Announces Extension of Deadline to Close Stratagene Merger Transaction.
Hycor and Stratagene File Amended Registration Statement on Form S-4.
Hycor and Stratagene File Amended Registration Statement on Form S-4.
Hycor and Stratagene Announce Effectiveness of Registration Statement Relating to Their Proposed Merger.
Stratagene Corp. Reports First Quarter Results for Stand-Alone Stratagene Operations; Year-Over-Year Revenue Up 15%; Net Income Grows 63%.
Stratagene Launches Mx3005P Real-Time QPCR System; Lowest Cost, High-Performance Real-Time QPCR Instrument Available.
Real-Time PCR: an Essential Guide.(polymerase chain reaction)(Book Review)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles